Open an account

Talphera

TLPH · NASDAQ

$1.07−$0.01 (−0.93%)TodayMarket closed ·
Prev close $1.08

About TLPH

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 12 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Employees
12
Headquarters
San Mateo, California
Listed
Feb 11, 2011
Sector
Health Care
Industry
Pharmaceuticals
Website
talphera.com

TLPH key statistics

Market cap
55.54M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
132.09K
Volume
19.21K
Open price
$1.09
High today
$1.11
Low today
$1.07
52 Week high
$1.57
52 Week low
$0.6866

Talphera (TLPH) at a glance

As of Oct 20, 2026, Talphera (TLPH) shares are priced at $1.07, giving the company a market cap of 55.54M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.07 and $1.11. The current price is 0.1% above the day's low and 3.6% below its high.

Volume so far is 19.21K shares, below the average of 132.09K shares a day.

Over the past year Talphera has ranged from $0.6866 to $1.57, and now sits 43% of the way up that range.

Talphera met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.06 per share against an estimate of -$0.068.

The average analyst price target is $3.23, 201.9% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $3.23
Low
$3.03
Now
$1.07
High
$3.67

TLPH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 29.6% on average.

  1. Q3 FY24: reported -$0.13 per share against an estimate of -$0.2091
  2. Q4 FY24: reported -$0.07 per share against an estimate of -$0.1632
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.153
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.102
  5. Q3 FY25: reported -$0.11 per share against an estimate of -$0.1428
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.0816
  7. Q1 FY26: reported -$0.04 per share against an estimate of -$0.0714
  8. Q2 FY26: reported -$0.06 per share against an estimate of -$0.068

TLPH news

  • Press releasePRNewswire

    Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releasePRNewswire

    Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

  • Press releasePRNewswire

    Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

  • Press releasePRNewswire

    Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

  • Press releasePRNewswire

    Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releasePRNewswire

    Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

  • Press releasePRNewswire

    Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Similar companies

Companies in the same industry as Talphera

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.